Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III perioperative HRS-4642 combination therapy versus standard treatment in resectable or borderline resectable pancreatic cancer
CTR20264028Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-4642 in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Started Oct 2026; status: active.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20264028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264028.